Susana Benlloch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Susana Benlloch has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Bartomeu Massutí
Hospital de la Ribera
4 shared publications- Jose Marcelo Galbis Caravajal
Hospital de la Ribera, 46600 Alzira, Spain
2 shared publications Santiago Romero
Department of Pneumology, Alicante University General Hospital, Alicante, Spain
2 shared publications- Antoni Castells
Gastroenterology, Hospital Clínic of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain
1 shared publication Artemio Payá
1 shared publicationConcepcion Martín
Department of Pneumology, Alicante University General Hospital, Alicante, Spain
1 shared publication
Latest Publications
- 20 November 2008
- Published by Springer Nature
- p. 337-347
Differentiation Between Malignant and Benign Pleural Effusions: Methylation Specific Polymerase Chain Reaction Analysis
- 20 November 2008
- Published by Springer Nature
- p. 337-347
Differentiation Between Malignant and Benign Pleural Effusions: Methylation Specific Polymerase Chain Reaction Analysis
- 1 November 2006
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 8 (5) , 540-543
Detection of BRAF V600E Mutation in Colorectal Cancer
- 1 November 2006
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 8 (5) , 540-543
Detection of BRAF V600E Mutation in Colorectal Cancer
- Open Access
Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion
BACKGROUND.: The objective of this study was to investigate the diagnostic value of methylation profiles for discrimination between malignant and benign pleural effusions. A secondary objective was to examine the concordance of methylation in samples of serum and pleural fluid.METHODS.: The authors used methylation‐specific polymerase chain reaction (MSP) analysis to examine the promoter methylation status of 4 genes in patients with pleural effusion: death‐associated protein kinase (DAPK), Ras association domain family 1A (RASSF1A), retinoic acid receptor β (RARβ), and p16/INK4a. Pleural effusions were collected from 87 patients who had their diagnoses confirmed on cytologic and/or histologic examinations and clinical evolution. Pleural effusions were classified as malignant (n = 53 patients) or benign (n = 34 patients).RESULTS.: Methylation was detected in serum from 45.3% of patients with malignant pleural effusions and from 0% of patients with benign pleural effusions, and it was detected in pleural fluid samples from 58.5% of patients with malignant pleural effusions and from 0% of patients with benign pleural effusions (P = .001). The sensitivity of MSP was greater than that of cytologic examination alone (39.1%; P = .001). When MSP was used together with cytologic examination, sensitivity increased to 69.8% (P = .001).CONCLUSIONS.: Cell‐free methylated DNA in pleural fluid can be detected in patients with neoplastic malignancy in a single extraction by thoracocentesis. Adequate management of the extracted pleural fluid can provide a rapid and reliable diagnosis in patients with pleural effusions who have suspected malignancy. MSP, used together with cytologic examination, may obviate the need for other invasive diagnostic tests. Cancer 2006. © 2006 American Cancer Society.
Open AccessPotential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion
BACKGROUND.: The objective of this study was to investigate the diagnostic value of methylation profiles for discrimination between malignant and benign pleural effusions. A secondary objective was to examine the concordance of methylation in samples of serum and pleural fluid.METHODS.: The authors used methylation‐specific polymerase chain reaction (MSP) analysis to examine the promoter methylation status of 4 genes in patients with pleural effusion: death‐associated protein kinase (DAPK), Ras association domain family 1A (RASSF1A), retinoic acid receptor β (RARβ), and p16/INK4a. Pleural effusions were collected from 87 patients who had their diagnoses confirmed on cytologic and/or histologic examinations and clinical evolution. Pleural effusions were classified as malignant (n = 53 patients) or benign (n = 34 patients).RESULTS.: Methylation was detected in serum from 45.3% of patients with malignant pleural effusions and from 0% of patients with benign pleural effusions, and it was detected in pleural fluid samples from 58.5% of patients with malignant pleural effusions and from 0% of patients with benign pleural effusions (P = .001). The sensitivity of MSP was greater than that of cytologic examination alone (39.1%; P = .001). When MSP was used together with cytologic examination, sensitivity increased to 69.8% (P = .001).CONCLUSIONS.: Cell‐free methylated DNA in pleural fluid can be detected in patients with neoplastic malignancy in a single extraction by thoracocentesis. Adequate management of the extracted pleural fluid can provide a rapid and reliable diagnosis in patients with pleural effusions who have suspected malignancy. MSP, used together with cytologic examination, may obviate the need for other invasive diagnostic tests. Cancer 2006. © 2006 American Cancer Society.
- 1 September 2006
- Published by Elsevier in Clinical Lung Cancer
- Vol. 8 (2) , 140-145
Cell-Free DNA Concentration in Pleural Fluid and Serum: Quantitative Approach and Potential Prognostic Factor in Patients with Cancer and Pleural Effusions
- 1 September 2006
- Published by Elsevier in Clinical Lung Cancer
- Vol. 8 (2) , 140-145
Cell-Free DNA Concentration in Pleural Fluid and Serum: Quantitative Approach and Potential Prognostic Factor in Patients with Cancer and Pleural Effusions